Abbvie Inc (ABBV)

$211.12 +3.94 (1.90%)
Market Cap 366.33B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 20.52
Forward PE 14.06
Profit Margin 6.91%
Debt to Equity Ratio -20.91
Volume 4,576,200
Avg Vol 7,382,988
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 41%
Beta 0.34
Analysts Strong Sell
Price Target $249.82

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
Guntz
Guntz Mar. 27 at 4:03 PM
$ABBV Well fun while it lasted lol
0 · Reply
67X_ROI_Q1_2026
67X_ROI_Q1_2026 Mar. 27 at 3:26 PM
$SLS the Market Cap, Market Value of SLS is up 1,600% in the last year since the IDMC Unblinded Actual Phase 3 Median Overall Survival and Immune Response Data - that told, everyone paying attention, GPS is 100% for Sure Getting Fda Approval - GUARANTEED. $ABBV $RHHBY and $BMY who own Aza and VEN - Know Precisely how their drugs work for AML Remission patients, they know GPS is the only reason we are and have been seeing Miraculous All Pooled Survival Data.
0 · Reply
Th3rston
Th3rston Mar. 27 at 3:14 PM
Can someone please let $ABBV know that the market's in a correction?
1 · Reply
Guntz
Guntz Mar. 27 at 2:12 PM
$ABBV It will be a battle here. Heavy supply zone
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Mar. 27 at 1:52 PM
$ABBV $204 was a good buy...
0 · Reply
middleman
middleman Mar. 27 at 1:00 PM
$ABBV lets go abbvie hang in there!
0 · Reply
NasdaqPulse
NasdaqPulse Mar. 27 at 11:36 AM
$ABBV income hunters, listen up Chasing $10,000/year in passive dividends? At today’s payout, that means roughly ~1.7K–2K shares depending on your cost basis and entry point. That’s the power of a steady dividend grower like AbbVie—cash flow you don’t have to “time the market” for. But here’s the catch Dividend safety matters Payout ratio + growth = long-term sustainability Reinvesting can dramatically lower your required share count over time This isn’t just about hitting $10K—it’s about compounding toward financial freedom. Do your own due diligence. Dividends are not guaranteed and can change.
0 · Reply
Tomrph
Tomrph Mar. 27 at 11:27 AM
$ABBV money moving to healthcare now? ABBV…lead the way
1 · Reply
67X_ROI_Q1_2026
67X_ROI_Q1_2026 Mar. 27 at 5:18 AM
$SLS $ABBV for the short bus riders, AZA+Ven, BAT, the Best Available Treatment for Control Patients in the SLS Phase 3 REGAL trial, recently FAILED 3 Large Phase 3 trials conducted by $ABBV, including Failing 2 for AML Remission Maintenance. it’s not at all complicated.
0 · Reply
Maxwell_Osgood
Maxwell_Osgood Mar. 27 at 1:50 AM
$ABBV helpful little bounce today...
0 · Reply
Latest News on ABBV
AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting

Mar 27, 2026, 10:00 AM EDT - 2 hours ago

AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting

AbbVie Named Official Pharmaceutical Partner of Major League Baseball

Mar 24, 2026, 8:00 AM EDT - 3 days ago

AbbVie Named Official Pharmaceutical Partner of Major League Baseball

US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings

Mar 20, 2026, 12:11 PM EDT - 7 days ago

US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings

AMRX NVS OGN

Buy Or Fear AbbVie Stock At $210?

Mar 19, 2026, 9:26 AM EDT - 8 days ago

Buy Or Fear AbbVie Stock At $210?

Best Dividend Kings: March 2026

Mar 19, 2026, 3:27 AM EDT - 8 days ago

Best Dividend Kings: March 2026

ABM ABT ADM ADP AWR BDX BKH

Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions

Mar 19, 2026, 3:00 AM EDT - 8 days ago

Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions

TrumpRx lists many medicines at prices higher than paid in UK

Mar 18, 2026, 2:23 PM EDT - 8 days ago

TrumpRx lists many medicines at prices higher than paid in UK

AMGN AZN BMY GILD GSK JNJ LLY

Big drugmakers must face US overcharge claims on medications for low-income patients

Mar 17, 2026, 2:32 PM EDT - 9 days ago

Big drugmakers must face US overcharge claims on medications for low-income patients

AZN NVS SNY

New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row

Mar 13, 2026, 9:00 AM EDT - 14 days ago

New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row

Harbor Health Care ETF Q4 2025 Portfolio Review

Mar 11, 2026, 8:18 AM EDT - 16 days ago

Harbor Health Care ETF Q4 2025 Portfolio Review

ABVX GMAB LLY MASI MEDI MRK RVMD

AbbVie Inc. (ABBV) Presents at Leerink Global Healthcare Conference 2026 Transcript

Mar 10, 2026, 2:10 PM EDT - 16 days ago

AbbVie Inc. (ABBV) Presents at Leerink Global Healthcare Conference 2026 Transcript

AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

Mar 9, 2026, 8:00 AM EDT - 18 days ago

AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

AbbVie Inc. (ABBV) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Mar 4, 2026, 2:02 AM EST - 23 days ago

AbbVie Inc. (ABBV) Presents at TD Cowen 46th Annual Health Care Conference Transcript

February Dividends With 4 Raises: 1.6% Up To 14.5%

Mar 3, 2026, 8:14 AM EST - 24 days ago

February Dividends With 4 Raises: 1.6% Up To 14.5%

BMY BTI MA

AbbVie to Present at the Leerink Partners Global Healthcare Conference

Mar 3, 2026, 8:00 AM EST - 24 days ago

AbbVie to Present at the Leerink Partners Global Healthcare Conference

AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease

Mar 2, 2026, 8:30 AM EST - 25 days ago

AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease

The High Dividend Yield Bull Market: 3 Compelling 6% Yields

Mar 2, 2026, 4:51 AM EST - 25 days ago

The High Dividend Yield Bull Market: 3 Compelling 6% Yields

AMGN AVGO BTI DIV ENB GTY JPM

Best Dividend Aristocrats For March 2026

Feb 27, 2026, 12:21 PM EST - 27 days ago

Best Dividend Aristocrats For March 2026

ABT ADM ADP AFL ALB AMCR AOS

Health Care Q4 Dividend Roundup: Merck Offers Thicker Dividend Cushion Than AbbVie

Feb 26, 2026, 7:30 AM EST - 4 weeks ago

Health Care Q4 Dividend Roundup: Merck Offers Thicker Dividend Cushion Than AbbVie

MRK

AbbVie to Present at the TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 8:00 AM EST - 4 weeks ago

AbbVie to Present at the TD Cowen 46th Annual Health Care Conference

AbbVie to invest $380 million to expand US manufacturing in Illinois

Feb 23, 2026, 12:03 PM EST - 4 weeks ago

AbbVie to invest $380 million to expand US manufacturing in Illinois

AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States

Feb 23, 2026, 11:00 AM EST - 4 weeks ago

AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States

U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

Feb 20, 2026, 2:00 AM EST - 5 weeks ago

U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

AbbVie Declares Quarterly Dividend

Feb 19, 2026, 9:37 AM EST - 5 weeks ago

AbbVie Declares Quarterly Dividend

AbbVie: Dominating Immunology While Building Oncology Upside

Feb 17, 2026, 1:11 AM EST - 5 weeks ago

AbbVie: Dominating Immunology While Building Oncology Upside

AbbVie Inc. (ABBV) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript

Feb 13, 2026, 12:57 PM EST - 5 weeks ago

AbbVie Inc. (ABBV) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript

54 Stocks, 9 Megatrends: My Favorite Places To Be While Capital Is 'Forced'

Feb 12, 2026, 7:30 AM EST - 6 weeks ago

54 Stocks, 9 Megatrends: My Favorite Places To Be While Capital Is 'Forced'

AM APH AR ASML AVAV BTU CARR

AbbVie sues US health agency over Botox price controls

Feb 11, 2026, 6:49 PM EST - 6 weeks ago

AbbVie sues US health agency over Botox price controls

Abbvie sues US health agency over Botox

Feb 11, 2026, 5:13 PM EST - 6 weeks ago

Abbvie sues US health agency over Botox

2 Urgent Sells And 2 No Brainer Dividend Buys

Feb 11, 2026, 4:06 PM EST - 6 weeks ago

2 Urgent Sells And 2 No Brainer Dividend Buys

AEP AMGN BMY ESS HASI HD PFE

Dividend Kings: No Ideal Buys In February's 57

Feb 10, 2026, 9:45 AM EST - 6 weeks ago

Dividend Kings: No Ideal Buys In February's 57

ABM ADP CWT FRT FTS HRL HTO

AbbVie: The Market Is Getting It Wrong

Feb 5, 2026, 8:52 AM EST - 7 weeks ago

AbbVie: The Market Is Getting It Wrong

AbbVie: Skyrizi And Rinvoq Growth Isn't Everything, But It's A Lot

Feb 5, 2026, 4:25 AM EST - 7 weeks ago

AbbVie: Skyrizi And Rinvoq Growth Isn't Everything, But It's A Lot

AbbVie: Double-Digit Growth For Immunology Products Continues With HUMIRA Surprise

Feb 4, 2026, 6:04 PM EST - 7 weeks ago

AbbVie: Double-Digit Growth For Immunology Products Continues With HUMIRA Surprise

AbbVie Q4 Earnings Review: I May Have Just Made A Huge Mistake

Feb 4, 2026, 5:45 PM EST - 7 weeks ago

AbbVie Q4 Earnings Review: I May Have Just Made A Huge Mistake

AbbVie's Immunology Fortress Can't Hide Cracks In Diversification (Downgrade)

Feb 4, 2026, 3:39 PM EST - 7 weeks ago

AbbVie's Immunology Fortress Can't Hide Cracks In Diversification (Downgrade)

AbbVie Inc. (ABBV) Q4 2025 Earnings Call Transcript

Feb 4, 2026, 1:20 PM EST - 7 weeks ago

AbbVie Inc. (ABBV) Q4 2025 Earnings Call Transcript

AbbVie's Inflammation Drug Humira Slows, But Skyrizi, Rinvoq Drive Revenue Growth

Feb 4, 2026, 12:38 PM EST - 7 weeks ago

AbbVie's Inflammation Drug Humira Slows, But Skyrizi, Rinvoq Drive Revenue Growth

AbbVie Revenue Rises on Immunology Growth

Feb 4, 2026, 8:34 AM EST - 7 weeks ago

AbbVie Revenue Rises on Immunology Growth

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway.

Feb 4, 2026, 8:18 AM EST - 7 weeks ago

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway.

AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugs

Feb 4, 2026, 7:51 AM EST - 7 weeks ago

AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugs

AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results

Feb 4, 2026, 7:48 AM EST - 7 weeks ago

AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results

Allergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle® Testimonial Program

Feb 3, 2026, 8:50 AM EST - 7 weeks ago

Allergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle® Testimonial Program

AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Adults and Adolescents With Vitiligo

Feb 3, 2026, 8:00 AM EST - 7 weeks ago

AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Adults and Adolescents With Vitiligo

Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance

Jan 29, 2026, 10:30 PM EST - 2 months ago

Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance

ABVX CVLT FIX FTAI GKOS GMAB HLI

10 Highest Rated Dividend Kings For Generations Of Income

Jan 29, 2026, 10:10 AM EST - 2 months ago

10 Highest Rated Dividend Kings For Generations Of Income

ABM ABT ADM BDX BKH KMB KO

AbbVie Launches Love in Mind™ to Spotlight the Emotional Impact of Migraine on Romantic Relationships

Jan 29, 2026, 8:00 AM EST - 2 months ago

AbbVie Launches Love in Mind™ to Spotlight the Emotional Impact of Migraine on Romantic Relationships

Allergan Aesthetics Unveils New Data Across Facial Injectables On-Market and Emerging Portfolio at IMCAS 2026 Showcasing Enduring Strength in Advancing Aesthetics Medicine

Jan 28, 2026, 8:00 AM EST - 2 months ago

Allergan Aesthetics Unveils New Data Across Facial Injectables On-Market and Emerging Portfolio at IMCAS 2026 Showcasing Enduring Strength in Advancing Aesthetics Medicine

US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks

Jan 27, 2026, 4:52 PM EST - 2 months ago

US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks

LLY PFE

The AbbVie Foundation Is Now Accepting Applications to Participate in the 2026 AbbVie Foundation Health Equity Accelerator

Jan 27, 2026, 9:34 AM EST - 2 months ago

The AbbVie Foundation Is Now Accepting Applications to Participate in the 2026 AbbVie Foundation Health Equity Accelerator

Guntz
Guntz Mar. 27 at 4:03 PM
$ABBV Well fun while it lasted lol
0 · Reply
67X_ROI_Q1_2026
67X_ROI_Q1_2026 Mar. 27 at 3:26 PM
$SLS the Market Cap, Market Value of SLS is up 1,600% in the last year since the IDMC Unblinded Actual Phase 3 Median Overall Survival and Immune Response Data - that told, everyone paying attention, GPS is 100% for Sure Getting Fda Approval - GUARANTEED. $ABBV $RHHBY and $BMY who own Aza and VEN - Know Precisely how their drugs work for AML Remission patients, they know GPS is the only reason we are and have been seeing Miraculous All Pooled Survival Data.
0 · Reply
Th3rston
Th3rston Mar. 27 at 3:14 PM
Can someone please let $ABBV know that the market's in a correction?
1 · Reply
Guntz
Guntz Mar. 27 at 2:12 PM
$ABBV It will be a battle here. Heavy supply zone
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Mar. 27 at 1:52 PM
$ABBV $204 was a good buy...
0 · Reply
middleman
middleman Mar. 27 at 1:00 PM
$ABBV lets go abbvie hang in there!
0 · Reply
NasdaqPulse
NasdaqPulse Mar. 27 at 11:36 AM
$ABBV income hunters, listen up Chasing $10,000/year in passive dividends? At today’s payout, that means roughly ~1.7K–2K shares depending on your cost basis and entry point. That’s the power of a steady dividend grower like AbbVie—cash flow you don’t have to “time the market” for. But here’s the catch Dividend safety matters Payout ratio + growth = long-term sustainability Reinvesting can dramatically lower your required share count over time This isn’t just about hitting $10K—it’s about compounding toward financial freedom. Do your own due diligence. Dividends are not guaranteed and can change.
0 · Reply
Tomrph
Tomrph Mar. 27 at 11:27 AM
$ABBV money moving to healthcare now? ABBV…lead the way
1 · Reply
67X_ROI_Q1_2026
67X_ROI_Q1_2026 Mar. 27 at 5:18 AM
$SLS $ABBV for the short bus riders, AZA+Ven, BAT, the Best Available Treatment for Control Patients in the SLS Phase 3 REGAL trial, recently FAILED 3 Large Phase 3 trials conducted by $ABBV, including Failing 2 for AML Remission Maintenance. it’s not at all complicated.
0 · Reply
Maxwell_Osgood
Maxwell_Osgood Mar. 27 at 1:50 AM
$ABBV helpful little bounce today...
0 · Reply
67X_ROI_Q1_2026
67X_ROI_Q1_2026 Mar. 27 at 1:11 AM
$SLS $ABBV Again, for the record, there are NO AML CR2 Patients Surviving at 24 months, absent transplant - in any published trial data any where ... this would include EVERY REGAL Eligible Patient, the Youngest and the So Called Healthiest and the MRD - ALL of them - and there is NIL survival at 24 months ... All 128 P3 Patients - 64 Control ARM on BAT - were enrolled 24 months ago. . . and there is NIL Survival even allowing for a small handful of Super Rare Outliers =/+/- 60 EVENTS and we AWAIT 80 ... BAT for Control is AZA +VEN, Aza+VEN Failed 3 Large Phase 3 Trials - including 2 for AML Remission Maintenance. HELLO??? it's not at all complicated.
0 · Reply
67X_ROI_Q1_2026
67X_ROI_Q1_2026 Mar. 27 at 12:41 AM
$SLS $ABBV AMONG ALL These BEGGING SHORT LOWLIFE - not 1 Can Answer... -- FIND 1 Trial where AML Cr2 Patients on BAT, are surviving at ALL at 24 months, absent transplant ... GO AHEAD LOWLIFE FIND 1.... ... You won't because YOU SHORT LOWLIFE LIARS CAN'T its been 24 months since enrollment completed 128 Patients - 64 Control Patients and there are Nil Survivors. Except a Rare Outlier =/+/- 60 EVENTS Just from the Control Arm While We Await 80 . . Gps Arm =+/- 19 / 20 ANY DAY NOW
1 · Reply
Guntz
Guntz Mar. 26 at 9:20 PM
$ABBV $215 is the 200ma. Would be amazing if we can test that tomorrow. Maybe wishful thinking but one can hope lol
1 · Reply
Stockman824
Stockman824 Mar. 26 at 8:17 PM
$ABBV $LLY $NVO $VKTX SOMETHING is LEAKING
0 · Reply
Guntz
Guntz Mar. 26 at 8:14 PM
$ABBV Would love for confirmation tomorrow. Hold $210 and clear $212 with conviction
0 · Reply
Theflash88
Theflash88 Mar. 26 at 7:51 PM
$VKTX Cmon $ABBV
0 · Reply
biolover
biolover Mar. 26 at 7:30 PM
$VKTX  CEO is relaxed ( when u listen to) seems happy with emerging Vanquish data. He indicated to Jeffries active partnering dialogue is ongoing. I would not under estimate pressure on $NVO , $ABBV and others to get something competitive with $LLY tirzepatide. Leaked news could be confused of who is acquiring who. ( seen with Merck RVMD ABBV ).
1 · Reply
67X_ROI_Q1_2026
67X_ROI_Q1_2026 Mar. 26 at 7:05 PM
$SLS $ABBV Phase 3 Registrational results are coming, and will give Gps the FDA Green Light to treat 100,000 AML Patients Currently in Remission. XCCo estimated $280K Rev Per Patient in Year 1. $28B Total Addressable Market - right out of the Gate, worth $40B to Big Pharma. This $5 stock will be $50 the Instant the P3 Results are Announced, and climbing. All P3 Patients were enrolled 24 + months ago, Phase 3 Results are Coming, - conceivably could be ANY DAY NOW. The Future is Inevitable.
0 · Reply
AllDayTrends
AllDayTrends Mar. 26 at 7:00 PM
POWER HOUR LARGE CAP TOP STOCKS $NFLX $ABBV $LIN $CVX
0 · Reply
Guntz
Guntz Mar. 26 at 6:34 PM
$ABBV I'll take this move and hope we don't fade but wish it had been on higher volume.
0 · Reply
middleman
middleman Mar. 26 at 6:32 PM
$ABBV oh yeah!! We bounced off the 204 nicely 🙏
0 · Reply
67X_ROI_Q1_2026
67X_ROI_Q1_2026 Mar. 26 at 6:22 PM
$ABBV up 2% today - or $7.3B - or 9 times the Value of all of $SLS.
1 · Reply